Vascular Biogenics Ltd. (VBLT) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET
Company Participants
Dan Ferry - LifeSci Advisors, IR
Dror Harats - CEO
Sam Backenroth - CFO
Conference Call Participants
Jonathan Aschoff - ROTH Capital Partners
Kevin DeGeeter - Oppenheimer
RK Ramakanth - H.C. Wainwright
Operator
Greetings, and welcome to the VBL Therapeutics First Quarter 2022 Earnings Confernce Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
I would now like turn the conference over to your host, Mr. Dan Ferry of LifeSci Advisors. Please go ahead, Dan.
Dan Ferry
Thank you, Operator. Good morning, everyone, and thank you for joining the VBL Therapeutics first quarter 2022 financial results and corporate update call. Joining me on the call is Professor Dror Harats, Chief Executive Officer; and Sam Backenroth, Chief Financial Officer. A press release with the company's financial results was issued earlier this morning and is available on the Investor Relations page of the VBL's website at vblrx.com.
Before turning the call over to Dror, and Sam, I would like to remind everyone that during this conference call, forward-looking statements made by management are intended to fall within the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, and Section 21E of the Securities Exchange Act of 1934, as amended.
As set forth in our press release, forward-looking statements involve risks and uncertainties that may affect the company's business and prospects, including those discussed in our filings with the SEC, which include, among other things, our annual report on Form 20-F and Form 6-K. These filings are available from the SEC or on our website.
Any forward-looking statements made on today's conference call
- Read more current VBLT analysis and news
- View all earnings call transcripts